	US 11,911,502 B1
	Pharmaceutical compositions and methods of using the same
Jeffrey M. Moshal, Allentown, PA (US); and Michael Libman, Allentown, PA (US)
Assigned to NODEN PHARMA DESIGNATED ACTIVITY COMPANY, Dublin (IE)
Filed by GENUS LIFESCIENCES INC., Allentown, PA (US)
Filed on Jul. 29, 2021, as Appl. No. 17/388,703.
Application 17/388,703 is a continuation of application No. 16/510,516, filed on Jul. 12, 2019, abandoned.
Application 16/510,516 is a continuation of application No. 15/934,562, filed on Mar. 23, 2018, granted, now 10,413,505, issued on Sep. 17, 2019.
Application 15/934,562 is a continuation in part of application No. 15/434,014, filed on Feb. 15, 2017, granted, now 10,231,961, issued on Mar. 19, 2019.
Application 15/434,014 is a continuation in part of application No. 15/427,011, filed on Feb. 7, 2017, granted, now 10,149,843, issued on Dec. 11, 2018.
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61M 19/00 (2006.01); A61P 23/02 (2006.01); A61B 17/24 (2006.01); A61K 31/46 (2006.01); A61B 1/233 (2006.01)

CPC A61K 9/0043 (2013.01) [A61B 17/24 (2013.01); A61K 31/46 (2013.01); A61M 19/00 (2013.01); A61P 23/02 (2018.01); A61B 1/233 (2013.01); A61B 2017/246 (2013.01)]

5 Claims

1. A method for induction of local anesthesia prior to performing a procedure on, through, or adjacent a mucous membrane of the nasal cavities of a patient comprising:

administering a pharmaceutical composition comprising:

about 3.5% to about 4.0% cocaine hydrochloride, in weight percentages based on total weight of the pharmaceutical composition,

about 0.7 mg/mL to about 1.3 mg/mL sodium benzoate, and

about 1.2 mg/mL to about 1.4 mg/mL citric acid,

provided that the pharmaceutical composition is an aqueous solution,

provided that the pharmaceutical composition has a pH of 2 to 4, and

provided that a concentration of benzoylecgonine in a volume of the pharmaceutical composition is at least 0.1 weight percent and does not exceed about 9.3 weight percent in the volume of the pharmaceutical composition after the volume of the pharmaceutical composition has been stored in a sealed container for six months at a temperature ranging from 38° C. to 42° C. and a relative humidity ranging from 70% to 80%.